Table 1.

Characteristics of included studies.

Author, year of publication	Country	Sample size		MLR value
		Cases	Controls	Cases	Controls	OR/HR	Sensitivity	Specificity
Wang et al 2015[8]	China	419	327	0.37 ± 0.23	0.16 ± 0.06	89.81 (53.18,151.68)
Fayed et al 2018[22]	Egypt	50	50	0.46 ± 0.30	0.15 ± 0.06		80	90
Ngahane et al 2019[24]	Cameroon	204	204	0.39 ± 0.23	0.19 ± 0.11		67.2	83.3
Manna et al 2017[3]	Italy	31	71	0.50 ± 0.20	0.18 ± 0.06		91.04	93.55
Liana et al 2019[23]	Indonesia	41	60	0.97 ± 0.51	0.57 ± 0.76		95.1	70
Rakotosamimanana et al 2015[20]	Madagascar	85	186	-	-	4.97 (1.3–18.99)
Rees et al 2020[26]	Tanzania	98	47	-	-		68	51
Choudhary et al 2019[18]	Kenya	13	67	0.48 ± 0.3	0.23 ± 0.2		77	78
Naranbhai et al2014[17]	South Africa*	12	1190	-	-	1.22 (1.07–1.4)
Naranbhai et al2014[11]	South Africa	1862		-	-	2.47 (1.39–4.40)
Ginderdeuren et al 2021[19]	South Africa	51	120	0.22 ± 0.16	0.34 ± 0.27	0.78 (0.59, 0.97)
Naranbhai et al2014[12]	South Africa	1336	-			1.23 (1.04-1.45)
				MLR before treatment	MLR after treatment
Wang et al 2015[8]	China	419	327	0.47 ± 0.21	0.22 ± 0.09
Iqbal et al 2014[21]	Pakistan	45	45	0.24 ± 0.14	0.19 ± 0.10
Okeke et al 2020[25]	Nigeria	60	60	0.11 ± 0.08	0.08 ± 0.06
Wang et al 2019[9]	China	151	129	0.47 ± 0.29	0.34 ± 0.5

^*South Africa, Tanzania, Uganda and Zimbabwe.

HR = Hazard ratio, MLR = Monocyte to lymphocyte ratio, OR = Odds ratio.